Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence
Vitamin K antagonists (VKA) and heparins have been utilized for the prevention and treatment of thromboembolism (arterial and venous) for decades. Targeting and inhibiting specific coagulation factors have led to new discoveries in the pharmacotherapy of thromboembolism management. These targeted an...
Main Authors: | Ali Zalpour, Thein Hlaing Oo |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2015-01-01
|
Series: | Advances in Hematology |
Online Access: | http://dx.doi.org/10.1155/2015/920361 |
Similar Items
-
Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence
by: Zalpour A, et al.
Published: (2014-11-01) -
Edoxaban in venous thromboembolism and stroke prevention: an appraisal
by: Proietti M, et al.
Published: (2016-02-01) -
Edoxaban for prevention of venous thromboembolism after major orthopedic surgery
by: Kawaji H, et al.
Published: (2012-05-01) -
Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK
by: Emilie Clay, et al.
Published: (2018-01-01) -
Risk impact of edoxaban in the management of stroke and venous thromboembolism
by: Hurst KV, et al.
Published: (2016-08-01)